| scholarly article | Q13442814 |
| P356 | DOI | 10.1007/S00415-013-6980-5 |
| P698 | PubMed publication ID | 23749294 |
| P50 | author | Marianne Rohrbach | Q51236258 |
| Thomas Hundsberger | Q56541747 | ||
| P2093 | author name string | Kai M Rösler | |
| Lukas Kern | |||
| P2860 | cites work | Enzyme replacement therapy with alglucosidase alfa in 44 patients with late-onset glycogen storage disease type 2: 12-month results of an observational clinical trial. | Q42629452 |
| 36 months observational clinical study of 38 adult Pompe disease patients under alglucosidase alfa enzyme replacement therapy | Q42634296 | ||
| Diagnostic efficacy of the fluorometric determination of enzyme activity for Pompe disease from dried blood specimens compared with lymphocytes-possibility for newborn screening | Q43208556 | ||
| Diagnostic criteria for late-onset (childhood and adult) Pompe disease | Q43802882 | ||
| Rate of disease progression during long-term follow-up of patients with late-onset Pompe disease. | Q44376591 | ||
| Orphan drugs for rare diseases: is it time to revisit their special market access status? | Q44871497 | ||
| Clinical trials of orphan medicines | Q45324849 | ||
| Pompe disease: from new views on pathophysiology to innovative therapeutic strategies | Q45866303 | ||
| Disease severity in children and adults with Pompe disease related to age and disease duration | Q47772980 | ||
| Safety and efficacy of recombinant acid alpha-glucosidase (rhGAA) in patients with classical infantile Pompe disease: results of a phase II clinical trial | Q47869064 | ||
| Enzyme replacement therapy in adult-onset glycogenosis II: is quantitative muscle MRI helpful? | Q50781892 | ||
| Observational clinical study in juvenile-adult glycogenosis type 2 patients undergoing enzyme replacement therapy for up to 4 years. | Q50790826 | ||
| Changes in skeletal muscle qualities during enzyme replacement therapy in late-onset type II glycogenosis: temporal and spatial pattern of mass vs. strength response. | Q51771787 | ||
| Making diagnosis of Pompe disease at a presymptomatic stage: to treat or not to treat? | Q54519754 | ||
| Long-term observational, non-randomized study of enzyme replacement therapy in late-onset glycogenosis type II | Q64042342 | ||
| Cerebral vascular accidents in patients over the age of 60. I. General considerations | Q74508594 | ||
| Carrier frequency for glycogen storage disease type II in New York and estimates of affected individuals born with the disease | Q77304104 | ||
| Cognitive and adaptive functioning of children with infantile Pompe disease treated with enzyme replacement therapy: long-term follow-up | Q83264951 | ||
| First experience with enzyme replacement therapy during pregnancy and lactation in Pompe disease | Q85034949 | ||
| Clinical features and predictors for disease natural progression in adults with Pompe disease: a nationwide prospective observational study | Q21202855 | ||
| Autophagy and mitochondria in Pompe disease: nothing is so new as what has long been forgotten | Q27015911 | ||
| Conditional tissue-specific expression of the acid alpha-glucosidase (GAA) gene in the GAA knockout mice: implications for therapy | Q28586585 | ||
| Chinese hamster ovary cell-derived recombinant human acid alpha-glucosidase in infantile-onset Pompe disease | Q30489156 | ||
| Recombinant human acid alpha-glucosidase enzyme therapy for infantile glycogen storage disease type II: results of a phase I/II clinical trial | Q33941289 | ||
| A randomized study of alglucosidase alfa in late-onset Pompe's disease | Q34110220 | ||
| Clinical manifestation and natural course of late-onset Pompe's disease in 54 Dutch patients | Q34554310 | ||
| Pompe disease diagnosis and management guideline. | Q34567528 | ||
| Screening for Pompe disease using a rapid dried blood spot method: experience of a clinical diagnostic laboratory | Q34608980 | ||
| Lysosomal storage diseases: diagnostic confirmation and management of presymptomatic individuals | Q34628634 | ||
| Consensus treatment recommendations for late-onset Pompe disease | Q34634354 | ||
| Enzyme replacement therapy in late-onset Pompe disease: a systematic literature review | Q34641771 | ||
| Early treatment with alglucosidase alpha prolongs long-term survival of infants with Pompe disease | Q35087282 | ||
| Methods of formal consensus in classification/diagnostic criteria and guideline development | Q35091202 | ||
| Survival and associated factors in 268 adults with Pompe disease prior to treatment with enzyme replacement therapy | Q35102705 | ||
| The natural course of non-classic Pompe's disease; a review of 225 published cases | Q36245480 | ||
| Methods for a prompt and reliable laboratory diagnosis of Pompe disease: report from an international consensus meeting | Q37031665 | ||
| Pompe disease: a review of the current diagnosis and treatment recommendations in the era of enzyme replacement therapy | Q37182561 | ||
| Pompe's disease | Q37302098 | ||
| Therapeutic approaches in glycogen storage disease type II/Pompe Disease. | Q37329535 | ||
| Management and treatment of glycogenosis type II. | Q37338760 | ||
| Diagnosis of glycogenosis type II. | Q37338764 | ||
| The Brazilian consensus on the management of Pompe disease. | Q37600014 | ||
| Glycoengineered acid alpha-glucosidase with improved efficacy at correcting the metabolic aberrations and motor function deficits in a mouse model of Pompe disease | Q38356012 | ||
| P433 | issue | 9 | |
| P921 | main subject | enzyme replacement therapy | Q916766 |
| P304 | page(s) | 2279-2285 | |
| P577 | publication date | 2013-06-08 | |
| P1433 | published in | Journal of Neurology | Q6295649 |
| P1476 | title | Swiss national guideline for reimbursement of enzyme replacement therapy in late-onset Pompe disease. | |
| P478 | volume | 260 |
| Q30398761 | Can stapedius reflex testing objectively measure muscle function in Pompe patients? |
| Q51717385 | Cessation and resuming of alglucosidase alfa in Pompe disease: a retrospective analysis. |
| Q39287288 | European consensus for starting and stopping enzyme replacement therapy in adult patients with Pompe disease: a 10-year experience. |
| Q34727909 | Objective consensus from decision trees |
| Q38800985 | Pompe Disease: Diagnosis and Management. Evidence-Based Guidelines from a Canadian Expert Panel |
| Q47404438 | Pompe disease in Austria: clinical, genetic and epidemiological aspects |
| Q35029971 | Pompe disease: literature review and case series |
| Q34151422 | The European Gaucher Alliance: a survey of member patient organisations' activities, healthcare environments and concerns |
Search more.